Get started
Author

K. Punie

ORCID: 0000-0002-1162-7963
Observed ORCID: 0000-0002-1162-7963
OpenAlex ID: A5073093064
LBA20 Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)
2025 · J.C. Cortés, A. Bardia, et al. · Annals of Oncology · 5
PDF
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
2026 · K.S. Saini, M. Koopman, et al. · Annals of Oncology · 3
PDF
Digital health technology in oncology: results from a survey by the ESMO Young Oncologists Committee and medical student alumni
2026 · P. Mandó, M. Moutafi, et al. · ESMO Real World Data and Digital Oncology · 1
PDF
Abstract RF6-05: Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study
2026 · K. Punie, S. M. Tolaney, et al. · Clinical Cancer Research · 1
250P Evolution of characteristics, real-world (rw) treatment (tx) landscape, and survival outcomes in patients (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) in the United States
2024 · K. Punie, A.W. Kurian, et al. · ESMO Open · 1
PDF
448P Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in the first line (1L) setting among patients with metastatic triple-negative breast cancer (mTNBC)
2026 · K. Punie, S.A. Hurvitz, et al. · ESMO Open
316TiP The LESLIE trial: Lifestyle interventions to enhance the efficacy of neoadjuvant systemic therapy in patients with triple-negative breast cancer
2026 · J. Van Cauwenberge, K. Dejaegher, et al. · ESMO Open
PDF
Abstract PS1-13-24: Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (chemo) for previously untreated advanced triple-negative breast cancer (TNBC) in patients (pts) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i)
2026 · S. Hurvitz, A. Bardia, et al. · Clinical Cancer Research
Abstract PS5-08-27: Single arm phase II study with abemaciclib and bicalutamide in locoregionally advanced inoperable or metastatic androgen receptor-positive triple-negative breast cancer (ABBICAR)
2026 · K. Borremans, A. Laenen, et al. · Clinical Cancer Research
396P Real-world treatment and survival outcomes in previously untreated patients with metastatic triple-negative breast cancer (mTNBC) in the United States (US)
2023 · K. Punie, A. Kurian, et al. · Annals of Oncology
PDF
Works count: 10
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type